Merck & Co., Inc. (BCBA:MRK)

Market Cap	416.03T +64.3%
Revenue (ttm)	94.36T +1.3%
Net Income	26.49T +6.6%
EPS	10,566.19 +8.0%
Shares Out	n/a
PE Ratio	15.70
Forward PE	22.81
Dividend	546.54 (1.57%)
Ex-Dividend Date	Dec 15, 2025

Volume	1,412
Average Volume	3,382
Open	35,300
Previous Close	34,760
Day's Range	34,040 - 35,300
52-Week Range	16,950 - 36,840
Beta	0.30
RSI	58.35
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD